OvaScience is a global life sciences company dedicated to improving fertility for women around the world.


Leadership Team

Executive Chair and Co-Founder

Dr. Dipp is a co-founder and Partner of Longwood Fund. Dr. Dipp has co-founded Longwood portfolio companies OvaScience (NASDAQ: OVAS) where she serves as Chairman of the Board and previously served as CEO, Axial Biotherapeutics, where she serves as Chairman of the Board, Alnara Pharmaceuticals (acquired by Eli Lilly), Verastem (NASDAQ: VSTM) and Flex Pharma (NASDAQ: FLKS). Previously, Dr. Dipp was the Senior Vice President and Head of GlaxoSmithKline’s (NYSE: GSK) Centre of Excellence for External Drug Discovery (CEEDD). Prior to leading GSK’s CEEDD, Dr. Dipp was the Vice President of Corporate Development at Sirtris (NASDAQ: SIRT acquired by GSK). Before joining Sirtris as a co-founder, she worked in healthcare private equity at The Wellcome Trust, London. Dr. Dipp serves on the Biotechnology Industry Organization (BIO) Emerging Companies Governing Board, the New England Venture Capital Association (NEVCA) Board, the Beth Israel Deaconess Medical Center Board of Directors, and the Boston Symphony Orchestra Board of Overseers. In 2015, Dr. Dipp was elected to join the World Economic Forum’s Young Global Leaders and was named to Fortune magazine’s 40 Under 40 list. Dr. Dipp is the women’s health contributor for Arianna Huffington’s Thrive Global.

Dr. Dipp holds a BM, BCh (MD equivalent) from University of Oxford Medical School and a DPhil (PhD equivalent) in Physiology from the University of Oxford. Dr. Dipp did her post-doctoral research in the departments of Pharmacology and Cardiothoracic Surgery, John Radcliffe Hospital, Oxford.

Chief Executive Officer Elect

Dr. Kroeger will join OvaScience as Chief Executive Officer in September 2017. He brings more than 20 years of experience leading, building and advising development-stage therapeutic and medical device companies, as well as the expertise of a physician and scientist. Most recently, he served as CEO of Cardioxyl Pharmaceuticals, leading teams that produced three investigational new drug candidates and successfully executed six Phase 1 and Phase 2 clinical studies, culminating in the sale of the company to Bristol Myers Squibb for $2.1 billion in total consideration. Prior to his position at Cardioxyl, he led investing efforts as aPartner at The Aurora Funds, a venture capital firm focused on early-stage biotechnology and medical device companies. Earlier in his career, he held positions at Genzyme and Decision Resources.

Dr. Kroeger earned his B.A. from Harvard University, his M.D. from Stanford University School of Medicine and did his Residency in General Surgery at the Brigham and Women’s Hospital, an affiliate of Harvard Medical School. He also holds his M.B.A. from Harvard Business School. Dr. Kroeger currently serves on the Board of Directors of CardioFocus, Inc. and Cantex Pharmaceuticals, Inc.

EVP, Research and Development

Dr. Luterman has been with OvaScience since January 2014 and most recently served as Senior Vice President, Research & Development. He brings over 20 years of industry experience to the Company. Prior to OvaScience, Dr. Luterman was an Early Development Team Leader at Shire Human Genetic Therapies, where he led the matrix management of Development Candidates from nomination through IND. Prior to Shire, he was a Program Leader at CombinationRx where he guided program strategy for the company’s flagship product and lead the development team through multiple clinical trials. Earlier in his career he worked at Biogen and Decision Resources Group, where he developed commercial analysis and recommendations for early stage clinical development programs.

Dr. Luterman holds a B.A. in Biology and Psychology from Bucknell University and a Ph.D. in Behavioral and Neural Sciences from Rutgers University. Dr. Luterman was a postdoctoral fellow at Mount Sinai School of Medicine in New York.